Analysts Offer Predictions for Precigen FY2027 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Investment analysts at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for shares of Precigen in a research report issued on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings of $0.18 per share for the year, down from their prior forecast of $0.20. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s FY2028 earnings at $0.40 EPS and FY2029 earnings at $0.66 EPS.

Separately, JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of Precigen in a report on Tuesday, January 14th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Precigen currently has a consensus rating of “Hold” and an average price target of $7.00.

Precigen Trading Up 0.6 %

Precigen stock opened at $1.81 on Friday. The firm has a market cap of $530.09 million, a P/E ratio of -3.29 and a beta of 1.58. Precigen has a 1-year low of $0.65 and a 1-year high of $2.17. The firm has a 50-day moving average of $1.61 and a 200-day moving average of $1.15.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02. The company had revenue of $1.19 million during the quarter, compared to analyst estimates of $1.30 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%.

Institutional Trading of Precigen

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Envestnet Asset Management Inc. raised its position in shares of Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 5,915 shares in the last quarter. Invesco Ltd. raised its holdings in Precigen by 14.6% in the fourth quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 6,040 shares in the last quarter. ProShare Advisors LLC lifted its position in Precigen by 26.6% during the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 10,900 shares during the period. Stoneridge Investment Partners LLC boosted its holdings in shares of Precigen by 21.3% during the 4th quarter. Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company’s stock valued at $77,000 after buying an additional 12,063 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Precigen by 12.0% in the 4th quarter. Wells Fargo & Company MN now owns 114,558 shares of the biotechnology company’s stock worth $128,000 after buying an additional 12,285 shares during the period. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.